[Form 4] EyePoint Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

EyePoint Pharmaceuticals (EYPT) Chief Financial Officer George Elston reported transfers of company common stock on September 19, 2025. The filing shows 20,000 shares were disposed of from Mr. Elston's direct holdings and the same number were recorded as held indirectly in an irrevocable family trust for the benefit of his children, with JP Morgan Trust Company of Delaware as trustee. After the reported transactions, Mr. Elston's direct beneficial ownership is reported as 62,114 shares and the Family Trust holds 20,000 shares. The filing also notes 1,266 shares were acquired on July 31, 2025 under EyePoint’s 2019 Employee Stock Purchase Plan. The reporting attorney-in-fact signed the form on September 22, 2025.

Insights

Securities Analyst

TL;DR: Insider moved 20,000 shares into a family trust; this is a reallocation of ownership, not an outright sale.

The Form 4 indicates a non-sale transfer where Mr. Elston reduced direct holdings by 20,000 shares while those shares became indirectly held via an irrevocable family trust. The transfer code G implies a gift or similar transfer; the price reported is $0.00, consistent with a non-cash transfer. Total direct ownership after the transaction is 62,114 shares. From a market-impact perspective, this is a change in beneficial ownership structure rather than a liquidity event, so it does not necessarily signal a change in insider conviction about the company’s prospects. Timing and scale should be considered relative to outstanding shares to judge materiality; that information is not provided in this filing.

Corporate Governance Expert

TL;DR: This appears to be estate or family planning via an irrevocable trust, a routine governance/ownership reorganization.

The disclosure shows the transferred shares are held in a trust for the reporting person’s children with JP Morgan Trust Company of Delaware as trustee and an explicit disclaimer of beneficial ownership by the reporting person. Such structures are commonly used for succession and tax planning. The Form 4 properly reports the transfer and the reporting person’s continuing indirect interest is disclosed. No change in executive role or compensation is disclosed here. The filing is procedurally complete based on the information provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Elston George

(Last) (First) (Middle)

C/O EYEPOINT PHARMACEUTICALS, INC.

480 PLEASANT STREET

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EyePoint Pharmaceuticals, Inc. [ EYPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/19/2025		G(1)		20,000	D	$0.00	62,114(2)	D
Common Stock	09/19/2025		G(1)		20,000	A	$0.00	20,000	I	By Family Trust(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On September 19, 2025, the reporting person transferred owned shares of Common Stock of the Company to an irrevocable family trust of which JP Morgan Trust Company of Delaware is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust").

2. Includes 1,266 shares acquired on July 31, 2025, pursuant to EyePoint's 2019 Employee Stock Purchase Plan.

3. These securities are held in a trust for the benefit of the reporting person's children. JP Morgan Trust Company of Delaware is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Remarks:

	/s/ Ron Honig, Attorney-in-Fact	09/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did EYPT CFO George Elston report on the Form 4?

He reported transferring 20,000 shares of EyePoint common stock on September 19, 2025, moving them into an irrevocable family trust.

Did George Elston sell shares of EYPT according to this filing?

No sale was reported. The transaction code and price of $0.00 indicate a transfer to a family trust rather than a market sale.

How many EYPT shares does Mr. Elston directly own after the transaction?

62,114 shares are reported as directly beneficially owned following the transaction.

How many shares are held in the family trust and who is the trustee?

20,000 shares are held in an irrevocable family trust for his children and JP Morgan Trust Company of Delaware is the trustee.

Were there any recent ESPP purchases reported in the filing?

Yes. The filing notes 1,266 shares were acquired on July 31, 2025 pursuant to EyePoint’s 2019 Employee Stock Purchase Plan.